1,721,173 research outputs found
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
No full textDiffuse large B-cell lymphoma (DLBCL)
can be divided into prognostically important
subgroups with germinal center Bcell–
like (GCB), activated B-cell–like
(ABC), and type 3 gene expression profiles
using a cDNA microarray. Tissue
microarray (TMA) blocks were created
from 152 cases of DLBCL, 142 of which
had been successfully evaluated by cDNA
microarray (75 GCB, 41 ABC, and 26 type 3).
Sections were stained with antibodies to
CD10, bcl-6, MUM1, FOXP1, cyclin D2,
and bcl-2. Expression of bcl-6 (P < .001)
or CD10 (P .019) was associated with
better overall survival (OS), whereas expression
of MUM1 (P .009) or cyclin D2
(P < .001) was associated with worse OS.
Cases were subclassified using CD10,
bcl-6, and MUM1 expression, and 64 cases
(42%) were considered GCB and 88 cases
(58%) non-GCB. The 5-year OS for the
GCB group was 76% compared with only
34% for the non-GCB group (P < .001),
which is similar to that reported using the
cDNA microarray. Bcl-2 and cyclin D2
were adverse predictors in the non-GCB
group. In multivariate analysis, a high International
Prognostic Index score (3-5) and
the non-GCB phenotype were independent
adverse predictors (P < .0001). In summary,
immunostains can be used to determine the
GCB and non-GCB subtypes of DLBCL and
predict survival similar to the cDNAmicroarray.
(Blood. 2004;103:275-282
- …
